You are hereBiocon

Biocon


Biocon introduces CIMIVIR-L™ for Hepatitis-C in India

Biocon Ltd, Asia's premier biotechnology company, introduces an advanced novel therapy CIMIVIR-L™ for the treatment of Hepatitis C in India. CIMIVIR-L™ is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of  the innovator product commercialized by Gilead Sciences in the US.


Career opportunity for Quality Assurance: Manager level in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Qauality Assurance: Manager level


Biocon is the Only Asian Company to be Ranked in Top 20 Global Biotech Employers for 2015

(BWI); Biocon Ltd has earned the distinction of being the only Asian Biopharma Company to feature among the top biotechnology employers in the world as ranked by Science magazine. The ranking is a result of a global survey conducted by the American Association for the Advancement of Science (AAAS) through its affiliate Science magazine to determine which companies in the biotech and pharmaceutical industry have the best reputations as employers globally.


Opportunity for Principal Scientist in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Principal Scientist


Biocon acquire Acacia Life Sciences' manufacturing unit

Biocon acquired a manufacturing unit of Vishakapatnam based Acacia Life Sciences for an undisclosed amount. The company has acquired business assets of the pharmaceutical manufacturing unit of Acacia Life Sciences with effect from October 1, on a going concern basis, Biocon said in a regulatory filing.


Vacancy as Senior Role in -Injectables / Fill Finish Manufacturing in Biocon

Biocon is a research-driven, global healthcare company with a strong matrix of capabilities along the biopharmaceutical value chain. Focusing on unmet medical needs in cancer, diabetes and inflammatory diseases, it offers novel therapies on a platform of affordable innovation.
Biocon together with group companies employs more than 2500 employees with approxmimately Rs 1,000 crore turnover and is expected to grow further during the current financial year.

Post: Senior Role in -Injectables / Fill Finish Manufacturing


Biocon's Earnings Surge in Q1 FY16

(Business Wire India); Biocon Ltd, Asia's premier biopharmaceuticals company, announced today that it has delivered a strong consolidated financial performance for Q1 FY16.


Biocon chairman got 2nd Rank in 'Medicine Maker Power List 2015'

Biocon’s chairman and managing director Kiran Mazumdar-Shaw, got  2nd rank in ‘The Medicine Maker Power List' 2015, an index of the 100 most influential people across the globe in the field of medicine. The top 5 in ‘The Medicine Maker Power List’ are: Anthony Fauci, director, National Institute of Allergy and Infectious Diseases, USA, Kiran Mazumdar-Shaw, chairman & managing director, Biocon, Sir Andrew Witty, chief executive officer, GlaxoSmithKline, Arthur D. Levinson, chief executive officer, Calico and Heather Bresch, chief executive officer of Mylan.


Biocon's net profit pushes by Exceptional items over 78% in Q4

Biocon, a leading innovation-led bio-pharmaceutical company, has announced satisfactory financial performance during the fourth quarter ended March 2014. Its consolidated net profit, after exceptional income of Rs. 105 crore on account of sale of Syngene shares, increased by 78.2 per cent to Rs. 201.54 crore from Rs. 113.08 crore in the corresponding period of last year. Operating profit jumped 4.7 percent year-on-year to Rs 202 crore for the quarter ended March 2015 from Rs 193 crore in the same quarter last year.Profit before tax and exceptional income also improved by only 4 per cent to Rs. 143.54 crore from Rs. 138.06 crore. EPS moved up to Rs. 10.08 from Rs. 5.76 crore.  Its consolidated net sales increased by 14.9 per cent to Rs. 830.38 crore during the fourth quarter from Rs. 722.59 crore in the same period of last year. Its pharma sales increased by 10.8 per cent to Rs. 594.91 crore from Rs. 536.77 crore and that of contract research & manufacturing services improved by 27.7 per cent to Rs. 248.92 crore from Rs. 194.90 crore.